Amgen says its Humira biosimilar ABP 510 hit its primary endpoint in Phase III tests comparing its lookalike of AbbVie’s blockbuster adalimumab based on the Psoriasis Area and Severity Index measure. The Thousand Oaks, CA, company said improvement in the PASI score was comparable in safety and immunogenicity after 16 weeks of treatment.
PASI was used to assess the redness, thickness and scaliness of the moderate-to-severe plaque psoriasis patients.
Humira has been a cornerstone product for AbbVie, accounting for 57% of the drugmaker’s 2013 sales, and continues to be a product for which the company is pursuing new indications. The latest roster of indications includes plaque psoriasis, ankylosing spondylitis, ulcerative colitis and rheumatoid arthritis.
Amgen’s lookalike is just one of six biosimilars the company is working on. Amgen expects to launch its biosimilar portfolio in 2017.
